ImageneBio, Inc. (IMA) Stock Forecast & Price Target
ImageneBio, Inc. · NASDAQ
$5.60+0.01 (+0.18%)
15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 2 firms covering ImageneBio, Inc, 1 rate it Buy or better, 0 sit at Hold, and 1 rate it Sell or worse, a hold consensus. The target range is very wide, $2.00 to $30.00 (about 15.0x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $16.00 sits 186% above the current $5.60. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-1.10 next quarter toward $-3.98 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS2 ratings
Hold
Strong Buy00%
Buy150%
Hold00%
Sell150%
Strong Sell00%
Based on 2 analysts giving stock ratings to ImageneBio, Inc.
As of Jul, 1 of 2 firms rate IMA a Buy (0 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
IMA EPS & revenue forecast
EPS · NEXT QUARTER
$-1.10
Range $-1.53 – $-0.84 · 3 analysts · -62% YoY
Next period, 3 analysts expect ImageneBio, Inc. to earn $-1.10 a share (range $-1.53 – $-0.84), versus $-2.91 a year earlier. Full-year consensus is $-4.10, growing to $-3.98 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 3 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering ImageneBio, Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on IMA.
#1
MF
Martin Fan
Wedbush
Sell
$2.00-64.3% to target
Coverage
—
+ Follow
#2
David Risinger
Leerink Partners
Buy
$30.00+435.7% to target
Coverage
—
+ Follow
IMA stock forecast FAQ
What is IMA's average 12-month price target?+
The 2 analysts with a live target average $16.00 for ImageneBio, Inc. over the next 12 months, ranging from a $30.00 high to a $2.00 low.
Is IMA stock a Buy, Sell or Hold right now?+
The current consensus is Hold. Of the 2 analyst ratings, 1 are Buy or Strong Buy, 0 are Hold, and 1 are Sell or Strong Sell.
What are the highest and lowest price targets for IMA?+
The Street-high target is $30.00 (Leerink Partners), and the Street-low is $2.00 (Wedbush). The average of all 2 active targets is $16.00.
How many Wall Street analysts cover IMA?+
2 analysts have an active rating on ImageneBio, Inc., and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering IMA?+
Among analysts who currently cover IMA, Martin Fan of Wedbush has the strongest overall Quantellect track record. Their current call is Sell with a $2.00 target.
What is ImageneBio, Inc.'s projected EPS for next quarter?+
The consensus estimate is $-1.10 per share (range $-1.53 – $-0.84) across 3 analysts. Full-year EPS is projected at $-4.10, rising to $-3.98 the following year.
How much revenue is ImageneBio, Inc. expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading IMA lately?+
As of Jul, 1 of 2 firms rate IMA a Buy (0 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their IMA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
